Biogen’s Q4 EPS and revenue topped estimates, but analysts cite Medicare changes and MS declines as headwinds. Leqembi and Skyclarys remain key growth drivers.
Latest Ratings for BIIB
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 2022 | Stifel | Downgrades | Buy | Hold |
| Mar 2022 | RBC Capital | Upgrades | Sector Perform | Outperform |
| Feb 2022 | Canaccord Genuity | Maintains | Buy |
